Shares of FibroGen Inc (NASDAQ:FGEN) have received a consensus recommendation of “Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $66.67.
A number of equities research analysts recently commented on the company. Zacks Investment Research upgraded FibroGen from a “sell” rating to a “hold” rating in a report on Friday, June 8th. ValuEngine upgraded FibroGen from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Mizuho reiterated a “buy” rating and issued a $61.00 price objective on shares of FibroGen in a report on Friday, June 1st. BidaskClub upgraded FibroGen from a “hold” rating to a “buy” rating in a report on Thursday, May 24th. Finally, TheStreet upgraded FibroGen from a “d” rating to a “c-” rating in a report on Tuesday, February 27th.
In other FibroGen news, CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction dated Thursday, April 5th. The stock was sold at an average price of $45.59, for a total value of $1,807,005.24. Following the completion of the sale, the chief executive officer now directly owns 2,950,813 shares in the company, valued at $134,527,564.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jorma Routti sold 6,000 shares of the stock in a transaction dated Monday, June 11th. The stock was sold at an average price of $57.48, for a total value of $344,880.00. Following the completion of the sale, the director now owns 137,540 shares of the company’s stock, valued at $7,905,799.20. The disclosure for this sale can be found here. Insiders sold 293,327 shares of company stock valued at $14,720,427 in the last quarter. 8.96% of the stock is currently owned by corporate insiders.
Shares of FibroGen traded up $0.45, hitting $59.85, during trading hours on Monday, according to Marketbeat.com. 13,131 shares of the stock traded hands, compared to its average volume of 525,511. The company has a quick ratio of 8.61, a current ratio of 8.61 and a debt-to-equity ratio of 0.19. FibroGen has a 1-year low of $28.50 and a 1-year high of $63.00. The firm has a market capitalization of $4.79 billion, a PE ratio of -34.54 and a beta of 1.95.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01. The business had revenue of $31.90 million during the quarter, compared to the consensus estimate of $29.07 million. FibroGen had a negative return on equity of 27.70% and a negative net margin of 102.86%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.48) earnings per share. analysts anticipate that FibroGen will post -1.58 EPS for the current year.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.